Goldman Sachs Initiates Coverage On Exact Sciences with Buy Rating, Announces Price Target of $160
Goldman Sachs analyst Matthew Sykes initiates coverage on Exact Sciences (NASDAQ:EXAS) with a Buy rating and announces Price Target of $160.
Goldman Sachs Initiates Coverage On NeoGenomics with Buy Rating, Announces Price Target of $55
Goldman Sachs analyst Matthew Sykes initiates coverage on NeoGenomics (NASDAQ:NEO) with a Buy rating and announces Price Target of $55.
Goldman Sachs Initiates Coverage On Myriad Genetics with Sell Rating, Announces Price Target of $25
Goldman Sachs analyst Matthew Sykes initiates coverage on Myriad Genetics (NASDAQ:MYGN) with a Sell rating and announces Price Target of $25.
Goldman Sachs Initiates Coverage On Invitae with Neutral Rating, Announces Price Target of $33
Goldman Sachs analyst Matthew Sykes initiates coverage on Invitae (NYSE:NVTA) with a Neutral rating and announces Price Target of $33.
Goldman Sachs Initiates Coverage On CareDx with Buy Rating, Announces Price Target of $95
Goldman Sachs analyst Matthew Sykes initiates coverage on CareDx (NASDAQ:CDNA) with a Buy rating and announces Price Target of $95.
Goldman Sachs Initiates Coverage On Quotient with Neutral Rating, Announces Price Target of $5
Goldman Sachs analyst Matthew Sykes initiates coverage on Quotient (NASDAQ:QTNT) with a Neutral rating and announces Price Target of $5.
Goldman Sachs Initiates Coverage On Organon with Neutral Rating, Announces Price Target of $35
Goldman Sachs analyst Terence Flynn initiates coverage on Organon (NYSE:OGNW) with a Neutral rating and announces Price Target of $35.
Goldman Sachs Initiates Coverage On Vontier with Neutral Rating, Announces Price Target of $40
Goldman Sachs analyst Joe Ritchie initiates coverage on Vontier (NYSE:VNT) with a Neutral rating and announces Price Target of $40.
Barclays Initiates Coverage On Arrival with Overweight Rating, Announces Price Target of $25
Barclays analyst Brian Johnson initiates coverage on Arrival (NASDAQ:ARVL) with a Overweight rating and announces Price Target of $25.
Barclays Reinstates Overweight on Intact Financial, Announces C$191 Price Target
Barclays analyst John Aiken reinstates Intact Financial (TSX:IFC) with a Overweight and announces C$191 price target.